Akribion Therapeutics Secures €8 Million Seed Financing to Advance RNA-Guided Technologies
Deal News | Feb 04, 2025 | PR Newswire Cision Akribion Therapeutics
Akribion Therapeutics, a German-based biotech firm, has emerged from stealth mode by completing an €8 million seed financing round. The financing is led by CARMA FUND and RV Invest, with participation from High-Tech Gründerfonds, among others. Akribion is gaining attention for its pioneering RNA-guided, nuclease-based technology for programmable cell depletion, which promises targeted cell annihilation in fields like oncology, autoimmune diseases, and fibrosis. Guided by co-CEOs Dr. Michael Krohn and Lukas Linnig, the company targets the HPV-induced Oropharyngeal Head & Neck Cancer first, with a wider range of therapeutic applications foreseen. Former BRAIN Biotech AG researcher Dr. Paul Scholz, the technology's principal inventor, leads R&D. Supported by an investment group, the funds will further in vivo proof of Akribion's G-dase® E technology, which precisely disrupts malignant cells' DNA/RNA without harming healthy cells. This positions Akribion’s platform as revolutionary in the rapid development of new treatments across various conditions.
Sectors
- Biotechnology
- Venture Capital
Geography
- Germany – Akribion Therapeutics is based in Zwingenberg, Germany, and the development and operations are centered there.
Industry
- Biotechnology – This article discusses a biotechnology company, Akribion Therapeutics, focusing on developing innovative technologies for programmed cell depletion within medical applications.
- Venture Capital – The article involves multiple venture capital participants, such as CARMA FUND and RV Invest, indicating a strategic investment in Akribion’s groundbreaking technology.
Financials
- €8 million – The seed financing amount raised by Akribion Therapeutics to develop its RNA-guided technology.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Akribion Therapeutics | Target Company | Company | A biotech company pioneering RNA-guided, nuclease-based technology for programmable cell depletion. |
| CARMA FUND | Lead Investor | Company | A venture capital investor leading the financing round for Akribion Therapeutics. |
| RV Invest | Lead Investor | Company | A venture capital firm participating in the financing round for Akribion Therapeutics. |
| High-Tech Gründerfonds | Investor | Company | A German investment firm participating in the seed funding round of Akribion Therapeutics. |
| Dr. Michael Krohn | Co-CEO | Person | Co-Founder and Co-CEO of Akribion Therapeutics, leading the company's strategic direction. |
| Lukas Linnig | Co-CEO | Person | Co-Founder and Co-CEO of Akribion Therapeutics. |
| Dr. Paul Scholz | Head of Research and Development | Person | Head of Research and Development at Akribion Therapeutics and principal inventor of G-dase E technology. |
| BRAIN Biotech AG | Original Developer | Company | The specialist firm in industrial biosolutions where G-dase E technology was discovered. |
| Dr. Martin Raditsch | General Partner | Person | General Partner at CARMA FUND, involved with Akribion's board and fundraising. |
| Dr. Aleksei Zeifman | Investment Director | Person | Investment Director at RV Invest, supporting Akribion Therapeutics. |
| Dr. Adel Nada | Board Chair | Person | Board Chair of Akribion Therapeutics and a biotech executive with venture partnerships. |